RAB8 enhances TMEM205-mediated cisplatin resistance

Pharmaceutical Research

Volumn 29, Issue 3, 2012, Pages 643-650

  Shen, Ding Wu ^a   Gottesman, Michael M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cisplatin resistance; RAB8; TMEM205

Indexed keywords

CELLUBREVIN; CISPLATIN; MEMBRANE PROTEIN; RAB PROTEIN; RAB8 PROTEIN; TRANSMEMBRANE 205 PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; RAB8A PROTEIN, HUMAN; TMEM205 PROTEIN, HUMAN;

ARTICLE; CANCER RESISTANCE; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG SENSITIVITY; EPIGENETICS; EXPRESSION VECTOR; GENE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SECRETION; RAB8 GENE; SQUAMOUS CELL CARCINOMA; TRANSMEMBRANE 205 GENE; UPREGULATION; DRUG RESISTANCE; GENETICS; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; HUMANS; MEMBRANE PROTEINS; RAB GTP-BINDING PROTEINS; TRANSFECTION; UP-REGULATION;

EID: 84862323429     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-011-0562-y     Document Type: Article

References (33)

1. Francia G, Man S,Teicher B,Grasso L,Kerbel RS. Gene expression analysis of tumor spheroids reveals a role for suppressed DNA mismatch repair in multicellular resistance to alkylating agents. Mol Cell Biol. 2004;24:6837-49.
2. Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the role of DNA repair pathways. Clin Cancer Res. 2008;14:1291-5.
3. Blair BG, Larson CA, Safaei R, Howell SB. Copper transporter 2 regulates the cellular accumulation and cytotoxicity of Cisplatin and Carboplatin. Clin Cancer Res. 2009;15:4312-21.
4. Konkimalla VB, Kaina B, Efferth T. Role of transporter genes in cisplatin resistance. In Vivo. 2008;22:279-83.
5. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003;22:7265-79.
6. Selvendiran K, Tong L, Vishwanath S, Bratasz A, Trigg NJ, Kutala VK, et al. EF24 induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by increasing PTEN expression. J Biol Chem. 2007;282:28609-18.
7. HallMD, Okabe M, ShenDW, LiangXJ,GottesmanMM. The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol. 2008;48:495-535.
8. Shen DW, Su A, Liang XJ, Pai-Panandiker A, Gottesman MM. Reduced expression of small GTPases and hypermethylation of the folate binding protein gene in cisplatin-resistant cells. Br J Cancer. 2004;91:270-6.
9. Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature. 2008;451:1116-20.
10. Pogribny IP, Filkowski JN, Tryndyak VP, Golubov A, Shpyleva SI, Kovalchuk O. Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Int J Cancer. 2010;127:1785-94.
11. Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J, et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 2008;68:425-33.
12. Borst P, Jonkers J, Rottenberg S. What makes tumors multidrug resistant? Cell Cycle. 2007;6:2782-7.
13. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002;2:48-58.
14. Howell SB, Safaei R, Larson CA, Sailor MJ. Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs. Mol Pharmacol. 2010;77:887-94.
15. Wang DS, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov. 2005;4:307-20.
16. Strausberg RL, Feingold EA, Grouse LH, Derge JG, Klausner RD, Collins FS, et al. Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proc Natl Acad Sci USA. 2002;99:16899-903.
17. Shen DW, Ma J, Okabe M, Zhang G, Xia D, Gottesman MM. Elevated expression of TMEM205, a hypotheticalmembrane protein, is associated with cisplatin resistance. J Cell Physiol. 2010;225:822-8.
18. Goud B, Gleeson PA.TGNgolgins,Rabs and cytoskeleton: regulating the Golgi trafficking highways. Trends Cell Biol. 2010;20:329-36.
19. Clark HF, Gurney AL, Abaya E, Baker K, Baldwin D, Brush J, et al. The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment. Genome Res. 2003;13:2265-70.
20. Ang AL, Taguchi T, Francis S, Folsch H, Murrells LJ, Pypaert M, et al. Recycling endosomes can serve as intermediates during transport from the Golgi to the plasma membrane of MDCK cells. J Cell Biol. 2004;167:531-43.
21. Chabrillat ML, Wilhelm C, Wasmeier C, Sviderskaya EV, Louvard D, Coudrier E. Rab8 regulates the actin-based movement of melanosomes. Mol Biol Cell. 2005;16:1640-50.
22. Gerges NZ, Backos DS, Esteban JA. Local control of AMPA receptor trafficking at the postsynaptic terminal by a small GTPase of the Rab family. J Biol Chem. 2004;279:43870-8.
23. Huber LA, Dupree P, Dotti CG. A deficiency of the small GTPase rab8 inhibits membrane traffic in developing neurons. Mol Cell Biol. 1995;15:918-24.
24. Kean MJ, Williams KC, Skalski M, Myers D, Burtnik A, Foster D, et al. VAMP3, syntaxin-13 and SNAP23 are involved in secretion of matrix metalloproteinases, degradation of the extracellular matrix and cell invasion. J Cell Sci. 2009;122:4089-98.
25. Bravo-Cordero JJ, Marrero-Diaz R, Megias D, Genis L, Garcia-Grande A, Garcia MA, et al. MT1-MMP proinvasive activity is regulated by a novel Rab8-dependent exocytic pathway. EMBO J. 2007;26:1499-510.
26. Henry L, Sheff DR. Rab8 regulates basolateral secretory, but not recycling, traffic at the recycling endosome. Mol Biol Cell. 2008;19:2059-68.
27. AlcindorT, BeaugerN. Oxaliplatin: a review in the era ofmolecularly targeted therapy. Curr Oncol (Toronto, Ont). 2011;18:18-25.
28. Kashiwagi E, Izumi H, Yasuniwa Y, Baba R, Doi Y, Kidani A, et al. Enhanced expression of nuclear factor I/B in oxaliplatin-resistant human cancer cell lines. Cancer Sci. 2011;102:382-6.
29. Tozawa K, Oshima T, Kobayashi T, Yamamoto N, Hayashi C, Matsumoto T, et al. Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer. Anticancer Res. 2008;28:2087-92.
30. Chen S, Liang MC, Chia JN, Ngsee JK, Ting AE. Rab8b and its interacting partner TRIP8b are involved in regulated secretion in AtT20 cells. J Biol Chem. 2001;276:13209-16.
31. Ghadially FN, Lock CJ, Yang-Steppuhn SE, Lalonde JM. Platinosomes produced in cultured cells by platinum coordination complexes. J Submicro Cytol. 1981;13:223-30.
32. Murray RZ, Wylie FG, Khromykh T, Hume DA, Stow JL. Syntaxin 6 and Vti1b form a novel SNARE complex, which is up-regulated in activated macrophages to facilitate exocytosis of tumor necrosis Factor-alpha. J Biol Chem. 2005;280:10478-83.
33. Zhang Y, Shu L, Chen X. Syntaxin 6, a regulator of the protein trafficking machinery and a target of the p53 family, is required for cell adhesion and survival. J Biol Chem. 2008;283:30689-98.